$160 Million is the total value of Prosight Management, LP's 46 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 113.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ALBO | Buy | ALBIREO PHARMA INC | $10,381,000 | +72.9% | 295,080 | +73.2% | 6.49% | +32.0% |
ARNA | Buy | ARENA PHARMACEUTICALS INC | $9,343,000 | +27.2% | 137,000 | +29.5% | 5.84% | -2.8% |
HAE | New | HAEMONETICS CORP MASS | $8,930,000 | – | 134,000 | +100.0% | 5.58% | – |
CUE | Buy | CUE BIOPHARMA INC | $7,344,000 | +8.1% | 630,364 | +13.2% | 4.59% | -17.4% |
ALDX | Buy | ALDEYRA THERAPEUTICS INC | $6,744,000 | +19.9% | 595,239 | +25.7% | 4.22% | -8.4% |
KZR | Buy | KEZAR LIFE SCIENCES INC | $5,559,000 | +24.3% | 1,023,704 | +36.4% | 3.48% | -5.1% |
XCUR | Buy | EXICURE INC | $5,400,000 | +798.5% | 3,600,000 | +1205.1% | 3.38% | +586.4% |
ZGNX | Buy | ZOGENIX INC | $5,284,000 | +38.8% | 305,788 | +56.8% | 3.30% | +6.0% |
ZBH | Buy | ZIMMER BIOMET HOLDINGS INC | $5,066,000 | +49.3% | 31,500 | +48.6% | 3.17% | +14.0% |
GLPG | Buy | GALAPAGOS NVspon adr | $4,960,000 | -3.1% | 72,000 | +8.4% | 3.10% | -26.0% |
CNVY | New | CONVEY HLDG PARENT INC | $4,670,000 | – | 410,412 | +100.0% | 2.92% | – |
KALV | New | KALVISTA PHARMACEUTICALS INC | $4,341,000 | – | 181,171 | +100.0% | 2.71% | – |
RCM | New | R1 RCM INC | $3,821,000 | – | 171,817 | +100.0% | 2.39% | – |
MORF | Buy | MORPHIC HLDG INC | $3,690,000 | +1021.6% | 64,292 | +1135.9% | 2.31% | +757.6% |
IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $3,614,000 | – | 138,886 | +100.0% | 2.26% | – |
MTCR | Buy | METACRINE INC | $3,303,000 | +74.9% | 869,082 | +185.4% | 2.06% | +33.6% |
QSI | New | QUANTUM SI INC | $2,788,000 | – | 227,391 | +100.0% | 1.74% | – |
LHCG | Buy | LHC GROUP INC | $1,980,000 | +17.9% | 9,888 | +12.6% | 1.24% | -10.0% |
ATIP | New | ATI PHYSICAL THERAPY INC | $1,653,000 | – | 173,276 | +100.0% | 1.03% | – |
IRTC | New | IRHYTHM TECHNOLOGIES INC | $1,340,000 | – | 20,200 | +100.0% | 0.84% | – |
New | ALBIREO PHARMA INCcall | $1,157,000 | – | 32,900 | +100.0% | 0.72% | – | |
EVH | New | EVOLENT HEALTH INCcl a | $1,099,000 | – | 52,023 | +100.0% | 0.69% | – |
CLOV | New | CLOVER HEALTH INVESTMENTS CO | $1,054,000 | – | 79,100 | +100.0% | 0.66% | – |
New | AURINIA PHARMACEUTICALS INCcall | $871,000 | – | 67,200 | +100.0% | 0.54% | – | |
NUVB | New | NUVATION BIO INC | $854,000 | – | 91,694 | +100.0% | 0.53% | – |
SIOX | Buy | SIO GENE THERAPIES INC | $699,000 | +30.2% | 256,115 | +24.4% | 0.44% | -0.7% |
OPCH | New | OPTION CARE HEALTH INC | $610,000 | – | 27,875 | +100.0% | 0.38% | – |
ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $578,000 | +122.3% | 149,090 | +163.9% | 0.36% | +69.5% |
XFOR | New | X4 PHARMACEUTICALS INC | $571,000 | – | 87,813 | +100.0% | 0.36% | – |
RPHM | New | RENEO PHARMACEUTICALS INC | $513,000 | – | 54,934 | +100.0% | 0.32% | – |
ORGO | Buy | ORGANOGENESIS HLDGS INC | $417,000 | +50.0% | 25,100 | +64.8% | 0.26% | +14.5% |
CANO | New | CANO HEALTH INC | $281,000 | – | 23,200 | +100.0% | 0.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G | 2024-01-02 |
13F-HR | 2023-11-14 |
SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.